Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 12/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699001 | 0.88 | TNIK (0.68) | TNIK | |
| SCHEMBL13224732 | 0.81 | TNIK (0.84) | TNIKMAPTLMNATP53POLB | |
| SCHEMBL2366947 | 0.79 | MAPT (0.56) | TNIKMAPTLMNATP53POLB | |
| SCHEMBL3393555 | 0.79 | MAPT (0.75) | TNIKMAPTLMNATP53POLB | |
| SCHEMBL3393548 | 0.79 | TNIK (1.00) | TNIKMAPTLMNATP53POLB | |
| SCHEMBL2367283 | 0.78 | PIP5K1C (0.69) | TNIKMAPTLMNATP53POLB | |
| SCHEMBL2366826 | 0.77 | TNIK (0.80) | TNIKMAPTLMNATP53POLB | |
| SCHEMBL2366210 | 0.76 | MAPT (0.79) | TNIKMAPTLMNATP53POLB | |
| SCHEMBL3394594 | 0.76 | TNIK (0.79) | TNIKMAPTLMNATP53POLB | |
| SCHEMBL3395759 | 0.76 | TNIK (0.79) | TNIKMAPTLMNATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364149-B1 | TNIK INHIBITOR AND THE USE | NAT CANCER CT (JP) | 2014-05-07 | — | — | EP | disclosed |
| CN-102227218-A | Tnik inhibitor and use thereof | TESSHI YAMADA | 2011-10-26 | — | — | CN | disclosed |
| EP-2364149-A1 | TNIK INHIBITOR AND THE USE | National Cancer Center (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| WO-2010064111-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | TNIK 1/4885MAPT 3204/4885LMNA 4362/4885 |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | TNIK 1/4885MAPT 2295/4885LMNA 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.